1Y Close · As of Aug 26, 2026
Penetrium Bioscience operates in the Professional Services sector.
Legal name: Penetrium Bioscience Inc.
In fiscal year 2024, Penetrium Bioscience (187660) reported revenue of 9.7 billion KRW, down 29.3% from 13.8 billion KRW a year earlier.
Operating profit was -15.9 billion KRW and net income was -20.3 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 213.5 billion KRW, with a P/B of 9.92.
These figures can be verified in the DART filing (receipt no. 20260226007165).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2024 | 9.7B | -15.9B | -20.3B |
| 2023 | 13.8B | -3.5B | -3.4B |
| 2022 | 14.9B | -755M | -59M |
Recent Filings
Officer/Major Shareholder Ownership Report
Semi-Annual Report (2026.06)
Securities Issuance Result (Voluntary Disclosure)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-27 | Officer/Major Shareholder Ownership Report |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-13 | Securities Issuance Result (Voluntary Disclosure) |
| 2026-08-13 | Securities Issuance Performance Report |
| 2026-08-11 | Subscription Results (Voluntary Disclosure) |